FRANKLIN LAKES, N.J. BD Diagnostics, a segment of BD (Becton, Dickinson and Company), today announced that a new study, "Universal Surveillance for Methicillin-Resistant Staphylococcus aureus in 3 Affiliated Hospitals," published in Annals of Internal Medicine, demonstrates that universal surveillance of all hospital admissions for methicillin-resistant Staphylococcus aureus (MRSA) using the BD GeneOhm(TM) MRSA real-time polymerase chain reaction (PCR) diagnostic test can significantly reduce MRSA infection rates.
Led by researchers at Evanston Northwestern Healthcare (ENH) in
Study authors report ENH reduced MRSA infection rates by 70 percent in less than two years. The reductions were significant in every category measured, such as surgical site, bloodstream, urinary tract and respiratory infections. Furthermore, this study indicates that limited active surveillance conducted only in the intensive care units did not produce the desired result, and that MRSA infections were significantly reduced only when universal all admissions testing was performed.
"BD is fully committed to the prevention of MRSA infections using active surveillance screening as a core component of a comprehensive infection prevention program," said